



CORRECTION

# Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review

Erica Velthuis · Julie Hubbard · Salvatore Longobardi · Thomas D'Hooghe

Published online: July 19, 2021  
© The Author(s) 2021

Correction to: Adv Ther (2020) 37:4831–4847  
<https://doi.org/10.1007/s12325-020-01512-w>

In the original article, there is an error in the second point of the Key Summary Points section. The correct statement is “In the published

literature, the adverse drug reaction rates for every 100,000 treatments started are 5190 (5.19%) for OHSS and no events reported for thromboembolism.”

---

The original article can be found online at <https://doi.org/10.1007/s12325-020-01512-w>.

---

E. Velthuis (✉)  
Global Patient Safety, Merck KGaA, Darmstadt, Germany  
e-mail: [erica.velthuis@merckgroup.com](mailto:erica.velthuis@merckgroup.com)

J. Hubbard  
Global Development and Medical, EMD Serono Research and Development Institute, Billerica, MA, USA

S. Longobardi  
Global Clinical Development, Merck Serono SpA, Rome, Italy

T. D'Hooghe  
Global Medical Affairs Fertility, R&D Biopharma, Merck KGaA, Darmstadt, Germany

T. D'Hooghe  
Department of Development and Regeneration, Biomedical Sciences Group, KU Leuven (University of Leuven), Leuven, Belgium

T. D'Hooghe  
Department of Obstetrics and Gynecology, Yale University, New Haven, USA

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.